Zacks Research Has Pessimistic View of TSE:BHC Q2 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research lowered their Q2 2025 earnings estimates for Bausch Health Companies in a research note issued to investors on Monday, June 23rd. Zacks Research analyst R. Department now anticipates that the company will earn $1.36 per share for the quarter, down from their previous forecast of $1.37. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.46 EPS, FY2025 earnings at $5.27 EPS, Q1 2026 earnings at $1.21 EPS, Q2 2026 earnings at $1.35 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.54 EPS, FY2026 earnings at $5.67 EPS, Q1 2027 earnings at $1.51 EPS and FY2027 earnings at $6.71 EPS.

Bausch Health Companies Stock Performance

BHC stock opened at C$8.74 on Thursday. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of -1,831.94. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$13.74. The company has a market cap of C$2.27 billion, a P/E ratio of -12.79, a PEG ratio of 0.21 and a beta of 0.77. The business has a fifty day moving average of C$7.04 and a 200-day moving average of C$8.94.

Insider Buying and Selling

In other Bausch Health Companies news, Director John Paulson acquired 502,688 shares of the business’s stock in a transaction that occurred on Thursday, June 12th. The shares were acquired at an average cost of C$7.44 per share, for a total transaction of C$3,739,596.57. Insiders bought a total of 3,553,401 shares of company stock worth $27,087,675 over the last three months. 11.28% of the stock is currently owned by company insiders.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.